Matulonis, Ursula A <br/><br/>
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.  [electronic resource] 

 -  Gynecologic oncology  Oct 2012 
 - 63-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1095-6859 
<br/><br/><label>Standard No.: </label>10.1016/j.ygyno.2012.06.040  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Aurora Kinases<br/>Azepines--adverse effects<br/>Disease-Free Survival<br/>Fallopian Tube Neoplasms--drug therapy<br/>Female<br/>Humans<br/>Middle Aged<br/>Ovarian Neoplasms--drug therapy<br/>Peritoneal Neoplasms--drug therapy<br/>Protein Kinase Inhibitors--therapeutic use<br/>Protein Serine-Threonine Kinases--antagonists & inhibitors<br/>Pyrimidines--adverse effects